187 related articles for article (PubMed ID: 35726891)
1. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer.
Liu H; Lin J; Zhou W; Moses R; Dai Z; Kossenkov AV; Drapkin R; Bitler BG; Karakashev S; Zhang R
Cancer Immunol Res; 2022 Aug; 10(8):1028-1038. PubMed ID: 35726891
[TBL] [Abstract][Full Text] [Related]
2. Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Dai B; Huang H; Guan F; Zhu G; Xiao Z; Mao B; Su H; Hu Z
Biomed Pharmacother; 2018 Mar; 99():72-80. PubMed ID: 29324315
[TBL] [Abstract][Full Text] [Related]
3. Histone demethylase KDM5A is transactivated by the transcription factor C/EBPβ and promotes preadipocyte differentiation by inhibiting Wnt/β-catenin signaling.
Guo L; Guo YY; Li BY; Peng WQ; Tang QQ
J Biol Chem; 2019 Jun; 294(24):9642-9654. PubMed ID: 31061100
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus type 16 E7 oncoprotein-induced upregulation of lysine-specific demethylase 5A promotes cervical cancer progression by regulating the microRNA-424-5p/suppressor of zeste 12 pathway.
Liu J; Zhao H; Zhang Q; Shi Z; Zhang Y; Zhao L; Ren Y; Ou R; Xu Y
Exp Cell Res; 2020 Nov; 396(1):112277. PubMed ID: 32918895
[TBL] [Abstract][Full Text] [Related]
5. Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells.
Váraljai R; Islam AB; Beshiri ML; Rehman J; Lopez-Bigas N; Benevolenskaya EV
Genes Dev; 2015 Sep; 29(17):1817-34. PubMed ID: 26314709
[TBL] [Abstract][Full Text] [Related]
6. Coordinated repression of cell cycle genes by KDM5A and E2F4 during differentiation.
Beshiri ML; Holmes KB; Richter WF; Hess S; Islam AB; Yan Q; Plante L; Litovchick L; Gévry N; Lopez-Bigas N; Kaelin WG; Benevolenskaya EV
Proc Natl Acad Sci U S A; 2012 Nov; 109(45):18499-504. PubMed ID: 23093672
[TBL] [Abstract][Full Text] [Related]
7. Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.
Yang GJ; Wang W; Mok SWF; Wu C; Law BYK; Miao XM; Wu KJ; Zhong HJ; Wong CY; Wong VKW; Ma DL; Leung CH
Angew Chem Int Ed Engl; 2018 Oct; 57(40):13091-13095. PubMed ID: 29968419
[TBL] [Abstract][Full Text] [Related]
8. Extended Recognition of the Histone H3 Tail by Histone Demethylase KDM5A.
Petronikolou N; Longbotham JE; Fujimori DG
Biochemistry; 2020 Feb; 59(5):647-651. PubMed ID: 31985200
[TBL] [Abstract][Full Text] [Related]
9. A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism.
Cui J; Quan M; Xie D; Gao Y; Guha S; Fallon MB; Chen J; Xie K
Oncogene; 2020 Jan; 39(5):1140-1151. PubMed ID: 31641207
[TBL] [Abstract][Full Text] [Related]
10. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
Du C; Lv C; Feng Y; Yu S
J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
[TBL] [Abstract][Full Text] [Related]
11. KDM5A controls bone morphogenic protein 2-induced osteogenic differentiation of bone mesenchymal stem cells during osteoporosis.
Wang C; Wang J; Li J; Hu G; Shan S; Li Q; Zhang X
Cell Death Dis; 2016 Aug; 7(8):e2335. PubMed ID: 27512956
[TBL] [Abstract][Full Text] [Related]
12. Effect of histone demethylase KDM5A on the odontogenic differentiation of human dental pulp cells.
Li QM; Li JL; Feng ZH; Lin HC; Xu Q
Bioengineered; 2020 Dec; 11(1):449-462. PubMed ID: 32208897
[TBL] [Abstract][Full Text] [Related]
13. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Gale M; Sayegh J; Cao J; Norcia M; Gareiss P; Hoyer D; Merkel JS; Yan Q
Oncotarget; 2016 Jun; 7(26):39931-39944. PubMed ID: 27224921
[TBL] [Abstract][Full Text] [Related]
14. H3K4me3 Demethylase Kdm5a Is Required for NK Cell Activation by Associating with p50 to Suppress SOCS1.
Zhao D; Zhang Q; Liu Y; Li X; Zhao K; Ding Y; Li Z; Shen Q; Wang C; Li N; Cao X
Cell Rep; 2016 Apr; 15(2):288-99. PubMed ID: 27050510
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of KDM5A for cancer treatment.
Yang GJ; Wu J; Miao L; Zhu MH; Zhou QJ; Lu XJ; Lu JF; Leung CH; Ma DL; Chen J
Eur J Med Chem; 2021 Dec; 226():113855. PubMed ID: 34555614
[TBL] [Abstract][Full Text] [Related]
16. Physical and functional interactions between the histone H3K4 demethylase KDM5A and the nucleosome remodeling and deacetylase (NuRD) complex.
Nishibuchi G; Shibata Y; Hayakawa T; Hayakawa N; Ohtani Y; Sinmyozu K; Tagami H; Nakayama J
J Biol Chem; 2014 Oct; 289(42):28956-70. PubMed ID: 25190814
[TBL] [Abstract][Full Text] [Related]
17. Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
Shokri G; Doudi S; Fathi-Roudsari M; Kouhkan F; Sanati MH
Leuk Res; 2018 May; 68():105-111. PubMed ID: 29602065
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of KDM5A in human cancer.
Yang GJ; Zhu MH; Lu XJ; Liu YJ; Lu JF; Leung CH; Ma DL; Chen J
J Hematol Oncol; 2021 Feb; 14(1):30. PubMed ID: 33596982
[TBL] [Abstract][Full Text] [Related]
19. Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.
Ohguchi H; Park PMC; Wang T; Gryder BE; Ogiya D; Kurata K; Zhang X; Li D; Pei C; Masuda T; Johansson C; Wimalasena VK; Kim Y; Hino S; Usuki S; Kawano Y; Samur MK; Tai YT; Munshi NC; Matsuoka M; Ohtsuki S; Nakao M; Minami T; Lauberth S; Khan J; Oppermann U; Durbin AD; Anderson KC; Hideshima T; Qi J
Blood Cancer Discov; 2021 Jul; 2(4):370-387. PubMed ID: 34258103
[TBL] [Abstract][Full Text] [Related]
20. Histone demethylase KDM5A is regulated by its reader domain through a positive-feedback mechanism.
Torres IO; Kuchenbecker KM; Nnadi CI; Fletterick RJ; Kelly MJ; Fujimori DG
Nat Commun; 2015 Feb; 6():6204. PubMed ID: 25686748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
